Osiris Therapeutics, Inc. Release: Grafix® Diabetic Foot Ulcer Clinical Trial Accepted for Presentation at the 2013 Symposium on Advanced Wound Care

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013. Dr. Larry Lavery, Principal Investigator and Professor of Plastic Surgery at the University of Texas Southwestern Medical Center, will discuss the primary and secondary endpoints as well as additional key safety data from the trial.

Help employers find you! Check out all the jobs and post your resume.